Fig. 1: Assessment of relationship between commercial and RUO versions of RS and EP scores. | npj Breast Cancer

Fig. 1: Assessment of relationship between commercial and RUO versions of RS and EP scores.

From: Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Fig. 1

Assessment of correlation (A) between commercial RS and RUO RS as well as (B) between commercial EP scores and RUO EP scores using the validation set (n = 48). Patients are represented in low-risk group with green, in intermediate-risk group with orange and in high-risk group with red as categorised by the commercial tests. RS: Recurrence Score; EP: EndoPredict; NS: NanoString; RUO: research use only.

Back to article page